Maggie L. Shaw

Adam Kittai, MD, weighs the favorable safety profile of acalabrutinib plus venetoclax against lingering unknowns on long-term efficacy and high-risk patients.

Diana Verrilli, MS, of Navista breaks down the regulatory, payer, and cybersecurity pressures threatening community oncology practices—and maps a path forward.

Bhavana (Tina) Bhatnagar, DO, explains how age, comorbidities, fertility, and individual goals drive personalized treatment decisions in ALL and AML.

Researchers found major differences between smoldering myeloma risk tools, raising concerns about overtreatment and defining “high risk.”

Efficacy and safety top the list for patients and physicians making R/R CLL treatment decisions, yet fewer than 1 in 3 patients felt their doctor fully answered their questions.

Nicholas Richardson, DO, MPH, discussed the implications of the FDA’s January draft guidance proposing MRD-negative complete response as a primary end point for accelerated approval in multiple myeloma.

Karilyn Larkin, MD, weighs in on how decitabine/cedazuridine/venetoclax could transform the AML treatment experience—and the new responsibilities it places on patients.

Taiho submitted the supplemental new drug application in April 2025 for decitabine/cedazuridine and venetoclax, and the FDA accepted it for review in July 2025.

Pediatric Sequential Organ Failure Assessment may better predict death in ALL and sepsis, supporting earlier ICU intervention.

Community pharmacists must build scalable workflows as bispecific antibodies move into earlier lines and outpatient settings, notes Brooke Peters, PharmD, BCOP, of AON.

Efgartigimod has recently been shown effective when investigated to treat ocular myasthenia gravis and juvenile myasthenia gravis.

Fears that the telemedicine boom would send health care costs soaring haven’t been borne out, a major new study finds, and the timing couldn’t be more critical for federal policy makers.

An NCCN Policy Summit webinar on May 7 warned that cancer care is failing patients, as poor health literacy, misinformation, and digital overload widen gaps in understanding.

Once-feared disease markers are losing their sting as targeted therapies reshape the landscape of ALL, Emily K. Curran, MD, told AJMC.

For BTK inhibitor selection in frontline CLL treatment, age, risk profile, and long-term sequencing strategy influence treatment decisions, says Kerry Rogers, MD.

Eileen Ehret, BS, Navista, focuses on aligning quality improvement with patient safety, engaging all stakeholders, and creating safe spaces to drive change in oncology.

These indications cover HIV, type 1 diabetes, chronic hives, genetic-related hearing loss, and lupus.

Karen Fancher, PharmD, BCOP, emphasizes a pharmacist’s pivotal role in CLL care through communication, adherence strategies, and bridging patients with medical teams.

Rose Gerber, MS, explains how listening, personal experience, and small steps can transform patients into powerful advocates for their own care.

Lekan Ajayi, PharmD, explains how remote therapy monitoring keeps patients with cancer on track with their care and reduces emergency visits.

New research incorporating Flatiron Health and SEER data, confirms community oncology care matches or beats other settings, says Diana Verrilli, MS, Navista.

Community oncology delivers top-tier cancer care close to home, said Nicolas Ferreyros, COA, championing research, advocacy, and innovation to prove it.

COA’s Christine Pfaff, RPh, MBA, highlights clinical and operational innovation, AI adoption, and practice-sharing as keys to advancing community oncology care.

COA's annual conference hits Orlando April 28, focusing on AI, targeted therapy innovation, and state-level oncology advocacy, explains cochair Johnetta Blakely, MD, MS, MMHC.

A French real-world study of 282 patients with CLL identified 2 distinct treatment profiles shaped by age, genetics, and logistics—not trial data alone.

Bispecific antibodies are delivering unprecedented response rates in multiple myeloma, offering fast, flexible options alongside CAR T-cell therapy, explains Prerna Mewawalla, MD.

A faster, cheaper alternative to karyotyping, DNA index testing shows near-perfect accuracy for detecting high hyperdiploidy in pediatric patients with leukemia.

Despite high rates of grade 3/4 infection, teclistamab was granted full approval by the FDA. Ajay K. Nooka, MD, speaks on how to optimally treat this adverse effect.

Time-limited acalabrutinib plus venetoclax improves outcomes vs chemoimmunotherapy, offering the first FDA-approved all-oral fixed-duration CLL option, explains Adam Kittai, MD.

A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age populations, explains Tina Bhatnagar, DO.